Cite
HARVARD Citation
Zhang, Q. et al. (2022). A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma. Leukemia & lymphoma. 63 (10), pp. 2503-2506. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhang, Q. et al. (2022). A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma. Leukemia & lymphoma. 63 (10), pp. 2503-2506. [Online].